Eli Lilly and Company

- There is no explicit mention or indication of any current or future plans for fundraising through debt or equity in the provided transcript pages from the Eli Lilly earnings call. - The CFO, Lucas Montarce, discusses operating margins, investment in R&D and SG&A, and financial outlook but does not reference raising capital through issuing debt or equity. - The company is focused on ramping up supply, demand generation, and expanding market access, supported by operational cash flow rather than external fundraising. - Other financial details include updated revenue and EPS guidance and expense expectations, with no indication of planned capital markets activity.

- Lilly continues to scale R&D and step up investments in manufacturing and commercial to support successful launches of new medicines such as Mounjaro, Jaypirca, Zepbound, Kisunla, and Ebglyss. (Page 3) - Massive investments have been made in parenteral filling capacity and active pharmaceutical ingredient (API) capacity to support production ramp-up, although full impact timelines extend 2-4 years. (Page 4) - Lilly is committed to expanding manufacturing capacity to meet demand, with ongoing acceleration in supply growth expected next year, based on capacity expansions announced over the last several years. (Page 5) - Investments include ramping up SG&A (selling, general and administrative expenses) and R&D to support demand generation activities and pipeline advancements. (Page 6) - Operating margin expansion is expected in the short term despite increased investments, supporting sustainable growth long term. (Page 6)

- Lilly expects strong revenue growth driven by key new products like Mounjaro and Zepbound, with U.S. sequential quarter-over-quarter prescription growth exceeding 25%. - Fourth quarter guidance anticipates about 50% growth, supported by increased demand generation efforts as supply constraints ease. - Continued expansion of Mounjaro into new countries outside the U.S. will contribute to volume and revenue growth. - Investments in marketing, selling, and demand stimulation activities are expected to accelerate sales, particularly for obesity and type 2 diabetes markets. - Operating margin expansion is forecasted in the short term; continued R&D and SG&A investments underpin sustained growth in the long term. - Pipeline advancements and new clinical starts, especially in oncology and immunology, are expected to fuel future product launches and revenue streams. - Manufacturing capacity expansions aim to support growing supply needs into 2025 and beyond, facilitating further market growth.

- Eli Lilly expects strong revenue growth, driven by products like Mounjaro and Zepbound, with Q4 projected at around 50% growth. - Operating margin expansion is anticipated in the short term, supported by increased investment in SG&A and R&D to drive growth. - Long-term strategy includes continued investment in demand generation and pipeline development, justifying sustained margin expansion. - Earnings per share (EPS) in Q3 2024 was $1.19, up significantly from $0.10 in Q3 2023, despite negative impacts from acquired IPR&D charges. - The company recognizes some short-term margin pressure due to scaling investments but expects these to pay off in future growth. - Strong pipeline advancements and manufacturing expansions support confidence in sustained profit growth. - Demand for incretin medicines is expanding, with improved supply enabling increased sales and prescription acceleration.

The transcript provided does not explicitly mention current or expected orderbook or pending orders figures. However, relevant insights include: - Demand for key products Mounjaro and Zepbound remains strong with sequential growth over 25%, indicating healthy ongoing orders. - Supply constraints experienced earlier in 2025 have largely been resolved; supply capacity is increasing with new manufacturing investments. - The company plans to accelerate demand generation activities (e.g., DTC advertising) to convert inventory to prescriptions once supply is ample. - Channel inventory experienced drawdowns in Q3 after restocking in Q2, reflecting typical channel stocking fluctuations rather than demand weakness. - Ongoing launches outside the US and ramp-up of supply capacity are expected to drive continued order growth into 2025. - No specific numeric orderbook or pending order data was disclosed in the excerpts.